Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.57 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684134 | 1.00 | STAT3 (0.57) | STAT3ADRB2ALDH1A1LMNANPSR1 | |
| SCHEMBL2969158 | 0.92 | ADRB2 (0.58) | ADRB2LMNATSHR | |
| SCHEMBL29684225 | 0.92 | ADRB2 (0.58) | ADRB2LMNATSHR | |
| SCHEMBL2973201 | 0.87 | ALOX15 (0.55) | ADRB2ALDH1A1LMNANPSR1SLC22A1 | |
| SCHEMBL23170017 | 0.84 | STAT3 (0.55) | STAT3ADRB2ALDH1A1LMNANPSR1 | |
| SCHEMBL2978394 | 0.83 | CALM1 (0.51) | ADRB2ALDH1A1CYP3A4NFKB1CALM1 | |
| SCHEMBL2975079 | 0.81 | TTR (0.50) | ADRB2ALDH1A1ADRB1 | |
| SCHEMBL1853092 | 0.81 | AKR1B1 (0.48) | CALM1 | |
| SCHEMBL30576431 | 0.81 | AKR1B1 (0.48) | CALM1 | |
| SCHEMBL2976761 | 0.80 | STAT3 (0.56) | STAT3ADRB2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | claimed |
| US-20200170907-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2020-06-04 | — | — | US | claimed |
| US-20160193126-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN INC (US) | 2016-07-07 | — | — | US | claimed |
| EP-1748767-A4 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS INC (US) | 2008-12-24 | — | — | EP | claimed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | claimed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | claimed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | claimed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | claimed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN, INC. (US) | 2024-01-02 | — | — | US | disclosed |
| CN-109134205-B | Diarylalkanes as potent inhibitors of binuclear enzymes | 尤尼根公司 | 2022-07-19 | — | — | CN | disclosed |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | UNIGEN PHARMACEUTICALS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1748767-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | Unigen Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005117849-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | UNIGEN PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200170907-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | STAT3 3754/4885ADRB2 2316/4885ALDH1A1 953/4885 |
| US-20050267047-A1 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | STAT3 3754/4885ADRB2 2316/4885ALDH1A1 953/4885 |
| US-20160193126-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | STAT3 3754/4885ADRB2 2316/4885ALDH1A1 953/4885 |
| US-20210085580-A1 | DIARYLALKANES AS POTENT INHIBITORS OF BINUCLEAR ENZYMES | TYR, DDT, HAAO | STAT3 3754/4885ADRB2 2316/4885ALDH1A1 953/4885 |
| US-20080132581-A1 | particularly tyrosinase; preventing and treating melanin overproduction; isolated from a plant family selected from the group consisting of Compositae, Fabaceae, Lauraceae, Leguminosae, Liliaceae, Loranthaceae, Moracea, and Myristicaceae | TYR, MAOA, CYP51A1 | STAT3 3714/4885ADRB2 3586/4885ALDH1A1 3005/4885 |
| US-11857657-B2 | Diarylalkanes as potent inhibitors of binuclear enzymes | TYR, DDT, HAAO | STAT3 3754/4885ADRB2 2316/4885ALDH1A1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.